A Phase 3 interventional study of Doravirine, Tenofovir, Lamivudine and ATRIPLA™ in Human Immunodeficiency Virus (HIV), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, with ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg, in treatment-naive participants infected with human immunodeficiency virus (HIV). The primary hypothesis is that doravirine, tenofovir, lamivudine q.d. is non-inferior to ATRIPLA™ q.d. as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48. This study has a total duration of 384 weeks, including a 96-week double-blind period and an additional 288-week open-label period.
Participants in Australia, Colombia, Guatemala, Honduras, Israel, New Zealand, Peru, Russia, South Africa, and Thailand who are deriving benefit from doravirine, tenofovir, lamivudine are also eligible to continue receiving study drug during additional open-label extensions which will last for 2 years or until drug is available locally, whichever comes first.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 734 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
Drug: Doravirine, Tenofovir, Lamivudine · Drug: Placebo
Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
Drug: ATRIPLA™ · Drug: Placebo
Drug pages: Doravirine · Tenofovir · Lamivudine
One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
Also known as: MK-1439A
One ATRIPLA™ tablet taken q.d. by mouth
Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
Time frame: Week 48
Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention).
Time frame: Up to Week 48
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.
Time frame: Week 96
Change From Baseline in CD4 Cell Counts at Week 48
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm\^3, and percent change was then calculated as \[(Baseline counts - Week 48 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in CD4 Cell Counts at Week 96
The mean change from baseline in CD4 cell counts at Week 96 were assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm\^3, and percent change was calculated as \[(Baseline counts - Week 96 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
Time frame: Baseline (Day 1) and Week 96
Percentage of Participants Experiencing ≥1 AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 48
Percentage of Participants Discontinuing From Study Medication Due to an AE(s)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to Week 48
Percentage of Participants With Tier-2 Neuropsychiatric AEs
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders".
Time frame: Up to Week 48
Change From Baseline in Fasting LDL-C at Week 48
The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Fasting Non-HDL-C at Week 48
The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Fasting Cholesterol at Week 48
The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Fasting Triglycerides at Week 48
The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline (Day 1) and Week 48
Change From Baseline in Fasting HDL-C at Week 48
The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
Time frame: Baseline (Day 1) and Week 48
Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA BLoQ at Week 96
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 was determined. Plasma HIV RNA levels was quantified with the Abbott RealTime HIV-1 Assay. Data was handled as observed.
Time frame: Week 96
Plasma Concentration of Doravirine at Week 48
Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.
Time frame: 0 hours post-dose and 2 hours post-dose on Week 48
Treatment-naïve participants with HIV-1 infection have been recruited at 141 study sites worldwide. The present results include results from the base study (first 96-weeks of the study) along with study extension 1 (week 96-192), study extension 2 (week 192-288), and study extension 3 (week 288-384).
| Milestone | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Started | 368 | 366 |
| Treated | 364 | 364 |
| Completed | 296 | 276 |
| Not completed | 72 | 90 |
| Withdrew: Death | 1 | 4 |
| Withdrew: Adverse event | 11 | 26 |
| Withdrew: Lack of efficacy | 31 | 23 |
| Withdrew: Lost to follow-up | 6 | 8 |
| Withdrew: Withdrawal by subject | 10 | 17 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Pregnancy | 2 | 2 |
| Withdrew: Protocol violation | 8 | 4 |
| Withdrew: Non-compliance with study drug | 1 | 4 |
| Milestone | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Started | 291 | 269 |
| Completed | 230 | 205 |
| Not completed | 61 | 64 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Lack of efficacy | 10 | 13 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Withdrawal by subject | 11 | 13 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Pregnancy | 4 | 2 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Availability of study drug locally | 22 | 19 |
| Withdrew: Non-compliance | 2 | 3 |
| Milestone | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Started | 192 | 173 |
| Completed | 150 | 132 |
| Not completed | 42 | 41 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 7 |
| Withdrew: Withdrawal by subject | 8 | 6 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Availability of study drug locally | 27 | 23 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Milestone | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Started | 121 | 111 |
| Completed | 100 | 85 |
| Not completed | 21 | 26 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Physician decision | 1 | 5 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Availability of study drug locally | 14 | 13 |
The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 | 84.3 | 80.8 |
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention).
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Dizziness | 8.8 | 37.1 |
| Sleep disorders and disturbances | 12.1 | 25.5 |
| Altered sensorium | 4.4 | 8.2 |
The percentage of participants in each arm with HIV-1 RNA levels \<50 copies/mL at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.
| Percentage of participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96 | 77.5 (72.8 to 81.7) | 73.6 (68.8 to 78.1) |
The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason.
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48 | 83.8 (79.6 to 87.4) | 79.7 (75.2 to 83.7) |
The percentage of participants in each arm with HIV-1 RNA levels \<40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses.
| Percentage of participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96 | 76.1 (71.4 to 80.4) | 72.8 (67.9 to 77.3) |
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm\^3, and percent change was then calculated as \[(Baseline counts - Week 48 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in CD4 Cell Counts at Week 48 | 198.4 (180.2 to 216.7) | 188.4 (169.5 to 207.2) |
The mean change from baseline in CD4 cell counts at Week 96 were assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm\^3, and percent change was calculated as \[(Baseline counts - Week 96 counts)\*100\]. CD4 cell counts were quantified by a central laboratory using a commercially available assay.
| Percentage Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in CD4 Cell Counts at Week 96 | 237.7 (214.9 to 260.6) | 223.0 (198.4 to 247.6) |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants Experiencing ≥1 AE | 82.7 | 90.7 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Percentage of participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants Discontinuing From Study Medication Due to an AE(s) | 3.0 | 6.6 |
The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders".
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Depression and suicide/self-injury | 4.1 | 6.6 |
| Psychosis and psychotic disorders | 0.3 | 1.1 |
The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in Fasting LDL-C at Week 48 | -1.58 (-3.98 to 0.81) | 8.74 (5.86 to 11.62) |
The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in Fasting Non-HDL-C at Week 48 | -3.83 (-6.27 to -1.40) | 13.26 (10.07 to 16.45) |
The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in Fasting Cholesterol at Week 48 | -1.97 (-4.74 to 0.79) | 21.77 (18.35 to 25.18) |
The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in Fasting Triglycerides at Week 48 | -12.40 (-19.66 to -5.15) | 22.01 (11.68 to 32.34) |
The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy.
| Percent Change from Baseline | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Change From Baseline in Fasting HDL-C at Week 48 | 1.86 (0.83 to 2.89) | 8.51 (7.32 to 9.69) |
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed.
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA Below the Limit of Quantification (BLoQ) at Week 48 | 59.6 | 55.5 |
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 was determined. Plasma HIV RNA levels was quantified with the Abbott RealTime HIV-1 Assay. Data was handled as observed.
| Percentage of Participants | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA BLoQ at Week 96 | 59.3 | 59.1 |
Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose.
| nM | MK-1439A (DOR/3TC/TDF From Day 1) |
|---|---|
| Pre-dose | 1290 ± 799 |
| 0.5 to 2 hours post-dose | 2330 ± 1230 |
Collected over Up to 430 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOR/3TC/TDF Only (From Day 1) at Base Study | 1/368 (0.3%) | 22/364 (6%) | 231/364 (63.5%) |
| DOR/3TC/TDF Switch at Week 96 Base Study | 4/366 (1.1%) | 30/364 (8.2%) | 281/364 (77.2%) |
| DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 1 | 2/291 (0.7%) | 19/291 (6.5%) | 111/291 (38.1%) |
| DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 1 | 0/269 (0%) | 12/269 (4.5%) | 110/269 (40.9%) |
| DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 2 | 2/192 (1%) | 8/192 (4.2%) | — |
| DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 2 | 2/173 (1.2%) | 9/173 (5.2%) | — |
| DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 3 | 0/121 (0%) | 2/121 (1.7%) | — |
| DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 3 | 0/111 (0%) | 7/111 (6.3%) | — |
| Event | DOR/3TC/TDF Only (From Day 1) at Base Study | DOR/3TC/TDF Switch at Week 96 Base Study | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 1 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 1 | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 2 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 2 | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 3 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 3 |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 2/111 |
| AppendicitisInfections and infestations | 1/364 | 1/364 | 0/291 | 1/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| SepsisInfections and infestations | 0/364 | 1/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| MyopericarditisCardiac disorders | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| InflammationGeneral disorders | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Clostridium difficile colitisInfections and infestations | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Cytomegalovirus colitisInfections and infestations | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Limb injuryInjury, poisoning and procedural complications | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Anaplastic large-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/364 | 0/364 | 0/291 | 0/269 | 0/192 | 0/173 | 0/121 | 1/111 |
| Event | DOR/3TC/TDF Only (From Day 1) at Base Study | DOR/3TC/TDF Switch at Week 96 Base Study | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 1 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 1 | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 2 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 2 | DOR/3TC/TDF Only (DOR/3TC/TDF From Day 1) Ext 3 | DOR/3TC/TDF Switch (Switch From EFV/FTC/TDF at Week 96) Ext 3 |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 37/364 | 139/364 | 2/291 | 4/269 | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | 50/364 | 58/364 | 16/291 | 17/269 | — | — | — | — |
| HeadacheNervous system disorders | 58/364 | 56/364 | 18/291 | 16/269 | — | — | — | — |
| NasopharyngitisInfections and infestations | 50/364 | 43/364 | 40/291 | 26/269 | — | — | — | — |
| RashSkin and subcutaneous tissue disorders | 20/364 | 50/364 | 8/291 | 5/269 | — | — | — | — |
| Abnormal dreamsPsychiatric disorders | 18/364 | 44/364 | 0/291 | 2/269 | — | — | — | — |
| NauseaGastrointestinal disorders | 31/364 | 42/364 | 5/291 | 7/269 | — | — | — | — |
| Upper respiratory tract infectionInfections and infestations | 41/364 | 30/364 | 21/291 | 19/269 | — | — | — | — |
| InsomniaPsychiatric disorders | 24/364 | 38/364 | 6/291 | 10/269 | — | — | — | — |
| PharyngitisInfections and infestations | 30/364 | 20/364 | 13/291 | 11/269 | — | — | — | — |
The Baseline Analysis Population consists of all randomized participants who received ≥1 dose of study drug.
| Age, Continuous(Years) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 33.6 ± 10.5 | 32.7 ± 9.9 | 33.1 ± 10.2 |
| Sex: Female, Male(Participants) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Female | 59 | 53 | 112 |
| Male | 305 | 311 | 616 |
| Race (NIH/OMB)(Participants) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 10 | 6 | 16 |
| Asian | 59 | 65 | 124 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 67 | 68 | 135 |
| White | 177 | 170 | 347 |
| More than one race | 51 | 55 | 106 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline cluster of differentiation 4 (CD4) cell counts(cells/mm^3) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 434.9 ± 217.9 | 415.5 ± 210.6 | 425.2 ± 214.3 |
| Baseline fasting low-density lipoprotein cholesterol (LDL-C)(mg/dL) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 92.08 ± 32.32 | 90.47 ± 30.64 | 91.27 ± 31.48 |
| Baseline fasting non-high-density lipoprotein cholesterol (non-HDL-C)(mg/dL) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 115.39 ± 34.67 | 114.63 ± 33.55 | 115.01 ± 34.09 |
| Baseline fasting cholesterol(mg/dL) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 157.29 ± 36.43 | 156.07 ± 36.51 | 156.68 ± 36.45 |
| Baseline fasting triglycerides(mg/dL) | MK-1439A (DOR/3TC/TDF From Day 1) | ATRIPLA™ (Switch From EFV/FTC/TDF at Week 96) | Total |
|---|---|---|---|
| Mean | 120.85 ± 83.06 | 123.23 ± 82.73 | 122.04 ± 82.84 |
1 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2015 to primary completion in Mar 2017, 21 months.
Results were first posted in Apr 2018, 1 year 1 month after primary completion.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 21 months is close to that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Tenofovir · Lamivudine
Acquired Immunodeficiency Syndrome →